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The protozoan parasite Cryptosporidium is an important cause of diarrheal disease
(cryptosporidiosis) in humans and animals, with significant morbidity and mortality
especially in severely immunocompromised people and in young children in low-resource
settings. Due to the sexual life cycle of the parasite, transmission is complex. There
are no restrictions on sexual recombination between sub-populations, meaning that
large-scale genetic recombination may occur within a host, potentially confounding
epidemiological analysis. To clarify the relationships between infections in different
hosts, it is first necessary to correctly identify species and genotypes, but these
differentiations are not made by standard diagnostic tests and more sophisticated
molecular methods have been developed. For instance, multilocus genotyping has been
utilized to differentiate isolates within the major human pathogens, Cryptosporidium
parvum and Cryptosporidium hominis. This has allowed mixed populations with multiple
alleles to be identified: recombination events are considered to be the driving force
of increased variation and the emergence of new subtypes. As yet, whole genome
sequencing (WGS) is having limited impact on public health investigations, due in part
to insufficient numbers of oocysts and purity of DNA derived from clinical samples.
Moreover, because public health agencies have not prioritized parasites, validation has
not been performed on user-friendly data analysis pipelines suitable for public health
practitioners. Nonetheless, since the first whole genome assembly in 2004 there are now
numerous genomes of human and animal-derived cryptosporidia publically available,
spanning nine species. It has also been demonstrated that WGS from very low numbers
of oocysts is possible, through the use of amplification procedures. These data and
approaches are providing new insights into host-adapted infectivity, the presence and
frequency of multiple sub-populations of Cryptosporidium spp. within single clinical
samples, and transmission of infection. Analyses show that although whole genome
sequences do indeed contain many alleles, they are invariably dominated by a single
highly abundant allele. These insights are helping to better understand population
structures within hosts, which will be important to develop novel prevention strategies
in the fight against cryptosporidiosis.
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INTRODUCTION
The parasite Cryptosporidium is a protozoan that occurs
worldwide, and can cause the diarrheal disease cryptosporidiosis
in humans and animals (Figure 1). The life cycle of
Cryptosporidium (Figure 2a) (1) is completed within a single
host. Both the asexual phase, and the production of thin-walled
oocysts that enable autoinfection, mean the numbers of parasites
are increased from possibly single figures in the initial infection,
to result in clinically significant infections and the shedding
of vast numbers of oocysts in feces (2). These shed oocysts
have thick walls, conferring protection for the four infective
sporozoites contained within, and enabling long-term survival,
environmental transmission, and resistance to commonly used
disinfectants including chlorine (3, 4). This means that, in
addition to the variety of hosts that act as direct sources of
infection (Figure 1; Table 1), contaminated food, water, or
environmental vehicles are involved in transmission and need to
be considered and investigated for effective disease control and
prevention of outbreaks of cryptosporidiosis (5).
Human cryptosporidiosis is usually a gastrointestinal disease,
although there is some evidence for respiratory cryptosporidiosis
in some populations (6). Symptoms ranging from mild to
severe depending upon a number of factors, including the
host’s age, immune status, nutrition, genetics, and the site
of infection, as well as the infecting species and variant of
Cryptosporidium (7–9). Clinical symptoms include diarrhea,
abdominal pain, vomiting, nausea, and low-grade fever, which,
although prolonged (2 weeks is not unusual) are generally
self-limiting in immune competent hosts. However, infection
can be more problematic and even life-threatening in some
severely immunocompromised individuals, and in malnourished
young children (10). There are few options for treatment or
prevention. Recent studies have shown that in some low-resource
countries, where access to safe drinking water, sanitation,
FIGURE 1 | Transmission of Cryptosporidium spp. leading to human
cryptosporidiosis, arrow thickness represents likely global importance of
source hosts.
hygiene, and healthcare is often poor, Cryptosporidium is one
of the most important causes of moderate-to-severe diarrheal
disease and death in young children (11, 12). Furthermore,
long-term effects of infection such as malnutrition, growth,
and cognitive deficits have been described, highlighting the
socio-economic impact on the adverse outcomes of infection
(10). A vicious cycle of malnutrition and diarrhea can become
established with detrimental effects on these societies (13). For
these reasons,Cryptosporidiumwas included in theWorldHealth
Organization’s Neglected Diseases Initiative in 2004 (14), which
served to raise awareness of the need for international and
national investments in prevention and control.
Thirty-nine species of Cryptosporidium have been described
at the time of writing (Table 1), but not all cause human disease.
The vast majority of human cryptosporidiosis is caused by
the zoonotic species Cryptosporidium parvum or anthroponotic
Cryptosporidium hominis, with multiple variants that can cause
varying severity of symptoms. The diagnostic target of laboratory
tests, and those used to detect Cryptosporidium in water, is
the oocyst, using stained microscopy or immunologically-based
assays, or the sporozoite DNA. Routinely applied tests are
not able to differentiate species, and molecular methods are
needed to investigate true relationships between infections and
contaminants and thus elucidate the complex transmission of
Cryptosporidium. A range of samples need to be investigated,
from feces (e.g., stools, diapers, livestock dung, manure, slurry,
runoff, and wild life droppings), to contaminated water and food,
but these present challenges to detection and genotyping. At
present, amplification by culture is not an option in this context,
and finding oocyst targets, which may be in low concentration in
the sample matrix, can be a hit-and-miss affair. Recent advances
in molecular methods generally, and particularly in genomics,
have increased the amount of data available particularly on the
major pathogenic Cryptosporidium species (Table 1). Continued
generation and accessibility of genomic data will potentially
improve the public health response to cryptosporidiosis by
identifying new targets for incorporation into diagnostic and
genotyping assays (15). Putative virulence and host adaption
factors have been proposed (16), and potential chemotherapeutic
targets and vaccine candidates are being sought (10, 17) and
identified [e.g., (18)].
INTRODUCTION TO CRYPTOSPORIDIUM
GENOTYPING
To identify Cryptosporidium species, genotyping was undertaken
initially using conventional PCR combined with either restriction
fragment length polymorphism (RFLP) or Sanger sequence
analysis, most commonly of the 18S rRNA gene (19). The 18S
rRNA gene includes conserved regions interspersed with highly
polymorphic regions and is currently considered to provide
the definitive sequences for discriminating Cryptosporidium
species. It is present in multiple copies (5 per sporozoite; 20
per oocyst) facilitating the development of sensitive assays,
which is especially important for testing samples such as water
where small (but potentially significant) numbers of oocysts
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FIGURE 2 | (a) The life cycle of Cryptosporidium (1). Oocysts (A) are ingested by the host, most likely as a mixed population of different genotypes; haploid
sporozoites (B) (variants are represented by red and blue) excyst and invade the brush border of epithelial cells; each sporozoite develops into a haploid trophozoite
with a prominent nucleus (C); the trophozoite undergoes merogony by mitosis to form a type I meront (D,E); up to eight haploid merozoites (F) are released, invade
(Continued)
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FIGURE 2 | another cell and undergo merogony again to form either further type I meronts (dotted line) or type II meronts (G), which release four haploid merozoites
(H) and form either microgamonts (I) that become multinucleate and mature to form multiple haploid microgametes (J) by mitosis, or a haploid macrogamont (K).
Microgamonts are released and potentially each fertilize a macrogamont to form a diploid zygote which undergoes sporogony by meiosis to produce either thin-walled
oocysts (L) containing four haploid sporozoites that can autoinfect the host (dotted line), or thick-walled oocysts (M) that are shed in the feces ready to transmit four
haploid sporozoites to a new host (the purple circle represents an oocyst that is the product of fertilization between the red and blue genotypes). (b) A simplified
schematic of genetic recombination in Cryptosporidium, potentially generating variation between sporozoites within oocysts. In a mixed infection population, different
fertilization scenarios potentially occur—between the same genotypes (resulting in identical daughter sporozoites) or between different genotypes, as in the example
shown, that result in a variety of outcomes depending on the random genetic exchange, or lack of, that occurs during meiosis. For simplicity only two example
chromosomes are shown with DNA from different genotypes represented by blue and red. The diploid zygote contains duplicate pairs of chromosomes, one set from
each parent cell; during interphase (In) the DNA in each chromosome is replicated to produce two identical sister chromatids held together with a centromere; in
prophase I (Pr I) the chromosomes start to condense and pair up with the homologous chromosome from the other parent cell, and cross-over can occur resulting in
an genetic exchange; during metaphase I (Me I) the paired chromosomes line up along the center of the cell and microtubules connect the centromeres to the
centrosomes (shown in green); during anaphase I (An I) each complete set of chromosomes (still paired as sister chromatids) are pulled toward each centrosome—the
chromosomes from either parent are randomly combined at this phase introducing a further opportunity for recombination (a blue and a red chromosome are drawn
to each centrosome in this example); in telophase I (Te I) the chromosomes start to unravel and cytokinesis starts to split the cell into two, resulting in two haploid cells;
in prophase II (Pr II) the chromosomes condense again; during metaphase II (Me II) the chromosomes line up along the center of the cells and microtubules connect
the centromeres to the centrosomes; this time during anaphase II (An II) the sister chromatids are separated and pulled apart toward the centrosomes, creating new
daughter chromosomes; finally in telophase II (Te II) the chromosomes unravel and cytokinesis starts to split the cells, which in the case of this example due to the
crossover event in prophase I, results in four genetically different haploid sporozoites. Depending upon whether random genetic exchanges take place between
chromosomes from different genotype parents (either in prophase I or anaphase I) the resulting haploid sporozoites can either be all different, two pairs of identical
sporozoites that are different from each parent, or two pairs of identical sporozoites that are the same as the two parents.
may be present. Species-level genotyping has provided improved
understanding of human epidemiology in some countries,
streamlined by the use of real-time PCR (see below). DNA
extraction methods from stool and gene targets have been
reviewed in detail by Khan et al. (17).
Beyond the species-level, Sanger sequencing part of the gp60
gene is most commonly used for further discriminating some
Cryptosporidium species, including C. parvum and C. hominis
(19–21). The gp60 gene is hypervariable both between and
within Cryptosporidium species, and the presence of a highly
variable serine repeat region in most species enables further
discrimination (19). For nomenclature of gp60 subtypes, the
reader is referred to a review of molecular epidemiologic tools
by Xiao and Feng (19). The use of this locus as a subtyping
marker has been questioned as it is associated with host cell
invasion, and therefore can be considered a virulence factor
under selective pressure. Nevertheless, as shown below, it may
still be an appropriate target for interrogation as a phenotype
determining biomarker. Another issue arises from the use of
a single locus; this may not be appropriate due to the genetic
recombination that occurs within Cryptosporidium populations
during the sexual stage of the life-cycle (Figure 2b). Whilst not
likely or expected between different species, this may occur in
populations of mixed subtypes of the same species (22–25). This
necessitates the investigation of multiple loci to reveal a more
accurate estimate of diversity and population structure (19, 26),
and would confer greater discrimination for characterization of
isolates (26, 27).
The reality is that genotyping tools are not currently
widespread in their application for public health purposes and in
most countries Cryptosporidium is under-diagnosed and isolates
are not characterized (28). In low-resource countries where
surveillance data are lacking, research studies have found that
C. hominis or human-adapted C. parvum subtypes predominate
(29, 30). C. parvum can also be the main species detected in
some urban settings with no animals close to residences, further
suggesting anthroponotic rather than zoonotic transmission (29).
These findings indicate that measures to improve sanitation
and hygiene would have greatest impact in these settings. Not
only is there a high prevalence of Cryptosporidium in these
populations, but there is also greater diversity within these
species, especially noticeable in C. hominis, than is seen in
industrialized countries (17, 31).
Genotyping in Cryptosporidium
Surveillance and Outbreaks
The aim of genotyping in the public health context is
to understand transmission and to improve the detection
resolution, investigation, and interpretation of waterborne,
zoonotic, person-to-person, and foodborne outbreaks. The
potential impact lies in:
• Identifying the Cryptosporidium species and subtypes that
most commonly cause human cryptosporidiosis, and their
demographic and temporal-spatial distribution
• Monitoring for the emergence of new species and subtypes in
human infection
• Improving detection, investigation, and interpretation
of outbreaks
• Increasing the sensitivity of epidemiological investigations to
identify links and risk factors, and identify the source of
outbreaks and contamination.
In most countries, routine surveillance captures Cryptosporidium
as an organism, but not species. Where genotyping is used to
inform public health, it is mainly in industrialized countries
but the framework varies. For example, in England and
Wales, clinical diagnostic laboratories have been sending
Cryptosporidium-positive stools for genotyping for many years,
both for molecular surveillance and for outbreak investigations,
and most diagnostic stools are genotyped (5, 32). In France,
testing for Cryptosporidium is not part of routine diagnostic
parasitological testing, but a national network of sentinel
laboratories was established to test for and genotype new and
outbreak cases of cryptosporidiosis (ANOFEL Cryptosporidium
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TABLE 1 | Cryptosporidium species, their major hosts, oocyst dimensions,
reported human infectivity and availability of genome data.
Cryptosporidium
species
Mean oocyst
dimensions
(µm)
Major
host(s)
Infections
reported in
humans
Genomes
available
(accession
number)
C. alticolis 5.4 × 4.9 Voles No No
C. apodemi 4.2 × 4.0 Mice No No
C. andersoni 7.4 × 5.5 Cattle Yes (rarely) PRJNA354069
C. avium 6.3 × 4.9 Birds No No
C. baileyi 6.2 × 4.6 Birds No PRJNA222835
C. bovis 4.9 × 4.6 Cattle Yes (rarely) No
C. canis 5.0 × 4.7 Canids Yes
(occasionally)
No
C. cuniculus 5.6 × 5.4 Lagomorphs,
Humans
Yes
(occasionally)
PRJNA315496
C. ditrichi 4.7 × 4.2 Mice Yes (rarely) No
C. ducismarci 5.0 × 4.8 Tortoises No No
C. erinacei 4.9 × 4.4 Hedgehogs Yes (rarely) No
C. fayeri 4.9 × 4.3 Marsupials Yes (rarely) No
C. felis 4.6 × 4.0 Felids Yes
(occasionally)
No
C. fragile 6.2 × 5.5 Toads No No
C. galli 8.3 × 6.3 Birds No No
C. homai Data not
available
Guinea Pigs No No
C. hominis 4.9 × 5.2 Humans Yes
(commonly)
PRJEB10000
PRJNA13200
PRJNA252787
PRJNA222836
PRJNA222837
PRJNA307563
PRJNA253838
PRJNA253839
PRJNA253834
C. huwi 4.6 × 4.4 Fish No No
C. macropodum 5.4 × 4.9 Marsupials No No
C. meleagridis 5.2 × 4.6 Birds,
mammals
Yes
(occasionally)
PRJNA222838
PRJNA315503
PRJNA315502
C. microti 4.3 × 4.1 Voles No No
C. molnari 4.7 × 4.5 Fish No No
C. muris 7.0 × 5.0 Rodents Yes (rarely) PRJNA32283
PRJNA19553
C. occultus 5.2 × 4.9 Rodents Yes (rarely) No
C. parvum 5.0 × 4.5 Mammals Yes
(commonly)
PRJNA144
PRJNA320419
PRJNA439211
PRJNA253848
PRJNA253843
PRJNA253845
PRJNA253836
PRJNA253840
PRJNA253846
PRJNA253847
PRJNA320419
PRJNA315506
PRJNA437480
PRJNA315504
PRJNA315508
PRJNA315507
PRJNA315505
PRJNA13873
(Continued)
TABLE 1 | Continued
Cryptosporidium
species
Mean oocyst
dimensions
(µm)
Major
host(s)
Infections
reported in
humans
Genomes
available
(Accession
number)
C. proliferans 7.7 × 5.3 Rodents,
maybe Equids
No No
C. proventriculi 7.4 × 5.7 Birds No No
C. rubeyi 4.7 × 4.3 Squirrels No No
C. ryanae 3.7 × 3.2 Cattle No No
C. scrofarum 5.2 × 4.8 Pigs Yes (rarely) No
C. serpentis 6.2 × 5.3 Reptiles No No
C. suis 4.6 × 4.2 Pigs Yes (rarely) No
C. testudinis 6.4 × 5.9 Tortoises No No
C. tyzzeri 4.6 × 4.2 Rodents Yes (rarely) No
C. ubiquitum 5.0 × 4.7 Mammals Yes
(occasionally)
PRJNA534291
PRJNA315509
PRJNA315510
C. varanii 4.8 × 4.7 Reptiles No No
C. viatorum 5.4 × 4.7 Humans,
Rodents
Yes
(occasionally)
PRJNA492837
C. wrairi 5.4 × 4.6 Guinea Pigs No No
C. xiaoi 3.9 × 3.4 Sheep, Goats No No
National Network, 2010). The Netherlands, Sweden and Scotland
also use sentinel laboratories to provide sporadic and outbreak
samples for genotyping in reference laboratories (28). In theUSA,
the Centers for Disease Control and Prevention is developing
CryptoNet, a molecular-based surveillance system aimed at the
systematic collection and molecular characterization of isolates
using 18S rDNA PCR-RFLP and gp60 sequencing (https://www.
cdc.gov/parasites/crypto/cryptonet.html). In Germany, Norway,
Spain, Ireland, Northern Ireland, Australia, and New Zealand,
Cryptosporidium genotyping has been used in epidemiological
research projects and/or for supporting outbreak investigations
(28, 33, 34), while the focus in Asia, Africa, and South
American countries has been on molecular epidemiological
research (29, 30, 35).
Molecular surveillance data in the United Kingdom (UK)
for example has shown that >95% of cases are caused by C.
hominis or C. parvum. Two seasonal peaks in cases occur, with C.
parvum consistently causing the majority of cases in spring and
C. hominis predominating in the autumn peak, with much higher
rates of foreign travel also reported during this second period
(32, 36–38). A similar temporal pattern has been reported in New
Zealand (39), but contrasts with the epidemiology in Ireland,
where there is no autumn peak and C. parvum predominates
all year (33, 40). This is likely due to the highly rural socio-
geography of Ireland and the greater potential of zoonotic
transmission, a feature also seen in rural regions of Great Britain
(36, 38). In the UK, the highest incidence of cryptosporidiosis is
in children under 5 years, with a second smaller peak in adults
in their 20s and 30s; in England and Wales in the period 2000 to
2003, C. hominis predominated in infants and the 30–39 year age
group (32), and in children <10 years and adults in the period
2004 to 2006 (37), suggesting transmission between children and
caregivers. In Ireland, where C. parvum predominates, the adult
peak does not appear but this may be a testing bias (33, 40).
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Although the sentinel surveillance in France is not wholly
representative of the French population due to the structure of
the network resulting in the inclusion of a higher proportion
of hospitalized cases (70%), particularly over-representing the
proportion of HIV-infected patients, certain trends are noticeable
(ANOFEL Cryptosporidium National Network, 2010). There
appears to only be a late summer/autumn peak each year, but the
case numbers per month were too low to determine any species-
related seasonality. However, C. parvum was more prevalent
each year compared to C. hominis (54.2 vs. 36.5%) and with
the remaining 9.4% representing other species (particularly C.
felis). The seemingly high number of unusual species were mainly
found in the over-represented immunocompromised patients
(82.8%), which may explain their higher prevalence than in the
UK for example.
In the Netherlands, only an autumn peak in case numbers
is present in surveillance data, and the predominant species
infecting people does not seem to be stable between years. One
study undertaken between 2003 and 2005 reported a higher
prevalence of C. hominis (70.3%) than C. parvum (18.7%), with
9.9% cases having both species, and a single case of C. felis (41).
The infecting species was significantly associated with patient
age, with children (aged 0–9 years) more frequently infected with
C. hominis and adults (over 25 years old) more frequently with
C. parvum (41). However, over a 3-year study from April 2013,
C. parvum was most prevalent in years one and two, but in
year three (April 2015 to March 2016) C. hominis predominated
and cases did not decline toward the winter as they had done
in previous years (42). Whether these apparent shifts were a
function of fluctuating participation in the sentinel scheme or
another reason is not known. In England and Wales apparent
shifts have also been seen; from 2000 to 2003 the ratio of C.
parvum:C. hominis nationally was close to 1, but in the period
2004–2006 it was 1:1.5, most noticeable in 2005 when it was
1:2.3 and major C. hominis outbreaks may have influenced the
distribution (37). The UK and the Netherlands both reported
an excess in cases of C. hominis with similar epidemiology in
the latter part of 2015, and despite gp60 sequencing identifying
subtype IbA10G2 and enhanced surveillance, no explanation was
found. This was the second time an international C. hominis
excess had been reported; in the late summer of 2012 the
Netherlands, UK, and Germany reported similarly unexplained
increases (43).
In the United States (US) national cryptosporidiosis
surveillance through CryptoNet is in its infancy, but there
seems to be a high diversity of Cryptosporidium species and
subtypes causing human cryptosporidiosis compared to other
industrialized nations (19). While C. hominis and C. parvum
cause the majority of cases, unusual species such as C. ubiquitum
and the chipmunk genotype are also seen, particularly in
rural areas and may suggest an important role of wildlife in
transmission, either directly or through drinking untreated water
(19). While general surveillance of Cryptosporidium species and
genotypes in the US is still fairly new, outbreak surveillance
has been carried out for many years through the National
Outbreak Reporting System (NORS). Analysis of 444 outbreaks
of cryptosporidiosis between 2009 and 2017 demonstrated most
were in the autumn and caused mainly by waterborne and
person-person transmission (44). Molecular data are available
for some of the outbreaks on the NORS website https://wwwn.
cdc.gov/norsdashboard/. Genotyping data for 131/178 (74%)
outbreaks in the same time period in England and Wales
showed 69 were caused by C. parvum (which caused all animal
and environmental contact and food-borne outbreaks, and a
minority of recreational water outbreaks), 60 were caused by
C. hominis (most of the recreational water and all person-to-
person spread outbreaks) and in two outbreaks both species
were identified (5). Both C. parvum and C. hominis caused
drinking waterborne outbreaks. Gp60 sequencing established
linkage between cases and suspected sources in nine animal
contact, three swimming pool, and one drinking water outbreaks
(5). Thus, the public health benefits of identifying infecting
species and subtypes lie in the ability to identify and strengthen
epidemiologic links between cases, and in indicating possible
exposures and sources to inform outbreak management (5).
However, the ability to differentiate zoonotic and anthroponotic
C. parvum routinely in all cases would be useful.
Identification by sequencing has established that unusual
species of Cryptosporidium, previously considered without
zoonotic potential, can infect people. Enhanced surveillance
has provided some understanding of the transmission of these
infections. In the UK, cases with unusual species often reported
zoonotic exposures; contact with unwell pets was a significant
association, and in particular, contact with cats was reported
by significantly more cases with C. felis (45). Genotyping C.
ubiquitum from patients in the US revealed mainly the rodent-
adapted subtype families (XIIb-XIId) in contrast to the UK
where infections weremainly the ruminant-adapted XIIa subtype
family (19, 46).
The potential for outbreaks is not limited to C. parvum
and C. hominis. In 2007 Cryptosporidium cuniculus (previously
rabbit genotype) was first identified in a patient during routine
molecular surveillance in the UK (47). The following year
an investigation into a drinking water quality incident in
England established that oocysts detected in treated water
were C. cuniculus. Soon afterwards, primary and secondary
C. cuniculus cases appeared in the supplied local population,
with the same gp60 subtype, VaA18 (48). Importantly, matching
the Cryptosporidium isolated from the drinking water, the
remains of a rabbit discovered in a chlorine contact tank,
and the case samples provided strong evidence for waterborne
transmission. This was the first outbreak reported to have
caused cryptosporidiosis where the etiological agent was a
species other than C. parvum or C. hominis, and established C.
cuniculus as a human pathogen. It re-enforced the importance
of protecting water supplies not only from livestock and sewage
contamination, but also from wildlife.
Sequencing of the gp60 gene has identified changes in the
circulation of predominant subtypes, and the emergence of
virulent subtypes. C. hominis IbA10G2 continues to predominate
in northern Europe, but in the US in 2007, 40 of 57 sporadic cases
from four states were a rare subtype, IaA28R4, with IbA10G2
accounting for just eight cases (49). Since 2013, IaA28R4 has
been displaced by IfA12G1R5 as the predominant C. hominis
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genotype in the US associated with both sporadic and outbreak
cases (19). In Africa and Asia there is greater variation in
C. hominis subtypes. For example, in Bangladesh where C.
hominis is the most common species (>95% of cases) and the
seasonality demonstrates a summer peak corresponding to the
monsoon, gp60 analysis revealed 13 different subtypes over a
2 year period (31). Some, for example IaA18R3 and IbA9G3
were present year on year, but other subtypes predominated in
some years and disappeared in subsequent years (e.g., IdA15G1
was very common in 2015, but not in 2016 when IaA19R3 and
IeA11G3T3 were dominant), indicating a dynamic and frequent
transmission (31).
In Europe there is more variation among C. parvum than
C. hominis, although IIaA15G2R1 and IIaA17G1R1 are often
(but not always) the most common (5, 19, 50). Genotyping
has increased our capacity to detect, investigate and interpret
outbreaks. For example, in 2012, C. parvum IIaA15G2R1 was
used as part of the case definition in an analytical study to
investigate a large outbreak (>300 cases) across England and
Scotland. A statistically significant association was identified
with consumption of pre-cut, bagged mixed salad leaves from
a specific national retailer (51). Also in 2012, an outbreak in
schoolchildren was associated with a visit to a holiday farm in
Norway (52). Genotyping of isolates from cases and potential
animal sources on the farm revealed the same rare subtype of
C. parvum, IIaA19G1R1, in the cases, lambs and goat kids (52).
The same holiday farm was also involved in a previous outbreak
in 2009 and the same subtype was identified retrospectively,
suggesting that in the absence of newly introduced subtypes,
existing subtypes can be stable and circulate on the farms for
many years (52).
Although gp60 sequencing has played an important role in
refining epidemiological investigations, it is somewhat surprising
that there is no standardized multilocus genotyping scheme for
Cryptosporidium surveillance and outbreaks. Additionally, the
lack of suitable markers has hampered our understanding of
the main transmission pathway (zoonotic or anthroponotic) of
Cryptosporidium species and subtypes. As discussed in this paper,
genomics has an important role to play in the identification
of new markers and the development of a MLG scheme, and
the aspiration is that application would eventually become
nationally systematic.
Multilocus Genotyping
Currently multilocus genotyping (MLG) is mainly applied to
study the population structure of Cryptosporidium spp. with
few reports describing its utility in surveillance or outbreaks.
One example is an investigation into a Swedish swimming
pool outbreak in 2002, where multilocus genotyping revealed
two concurrent C. parvum outbreaks, with different subtypes
linked to the use of either the indoor or outdoor pool,
indicating multiple contamination events (53). In England, the
epidemiological association of C. parvum cases with a drinking
water supply was strengthened by MLG (54). However, more
often investigations have explored the population structure and
biology of Cryptosporidium.
In 2015, Widmer and Caccio investigated the relationship
between sequence and length polymorphism within a set of
biomarkers in the Cryptosporidium genome. They compared
genetic distances of sequence and length polymorphism, finding
that there was a weak correlation between the two distance
measures. Their results also indicated that the resolution of
Cryptosporidium population structure was dependent on the
genotyping method used (55). Differences in varying extents of
host-associated (56, 57) and geographical segregation (24, 58–
60), and the extent of panmixia vs. clonality, depending on
the population studied (21), have been reported. For example,
in Spain, C. parvum in cattle herds was reported to show a
panmitic population structure contrasting with sheep where C.
parvum populations appeared more clonal (19, 61, 62). This may
have been a function of the predominance of C. parvum gp60
subtype family (IId) in sheep in the study region of Northeastern
Spain (63) as IId has been reported to be clonal in other
regions/countries (64).
Pamixia in Cryptosporidium spp. may reflect the increased
potential for genetic recombination between more diverse
isolates than is available in these supposed clonal populations of
parasites. The presence ofmixed populations withmultiple alleles
is the driving force of increased variation and the emergence
of new subtypes due to recombination events (65–67). In some
studies, for example in Scotland C. hominis populations have
shown clonality (58), but in a cohort of children in Peru,
genetic recombination was detected in some C. hominis IbA10G2
samples using MLST of 32 polymorphic loci, despite the overall
clonality of the C. hominis population (65).
However, with the vast majority of C. hominis isolates in many
areas, including northern Europe and Australia, demonstrating
the dominant IbA10G2 (21) the potential for recombination
with other more diverse subtypes may be reduced through lack
of exposure in those regions. In contrast, the wide variety of
different C. parvum subtypes usually present in local geographic
areas make mixed populations more likely. This has been
suggested in a study of the global population structures of
both Cryptosporidium species, where samples from Uganda
showed similar panmitic population structures, contrasting with
C. hominis samples from the United Kingdom and C. parvum
from New Zealand which showed much more clonal population
structures (68). The authors suggest that both C. parvum and
C. hominis population structures appear to be shaped by local
or host-related factors rather than being species-specific (68).
This was borne out by a study in Sweden that applied a nine-
locus SNP-based method to differentiate C. hominis IbA10G2
and grouped 44 isolates, from 12 countries (including 7 non-
European), into 10 MLSTs with known epidemiologically-linked
samples clustering together; geographical clustering was not
obvious, however the numbers of isolates from each country were
small (69). In the USA, the emergence and spread of C. hominis
IaA28R4 was investigated by sequencing eight loci (67). Of 95
C. hominis samples (62 IaA28R4 samples) from four states, the
sequence diversity identified two clear sub-populations separated
geographically between Ohio and three southwestern states,
and suggested that the Ohio subpopulation was a descendant
of the subpopulation in the southwestern states. Furthermore,
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genetic recombination was seen to occur in IaA28R4 isolates and
was likely an important factor in its emergence (67), a finding
supported by a comparative study of the genome along with the
previously dominant IbA10G2 subtype (70).
For disease surveillance and outbreak investigations, there is
a need to establish a common multilocus genotyping scheme
to track the sources and spread of infection. In a review
published in 2012, Robinson and Chalmers reported that
different combinations of loci and methods of analysis had
been used, with very few groups using comparable loci (27).
For public health purposes it is desirable to have consensus
to enable cross-boundary comparisons and investigations and
track international spread. An initiative funded by EU COST
Action FA1408 “A European Network for Foodborne Parasites:
Euro-FBP” (http://www.euro-fbp.org) enabled a workshop to
be held between 23 scientists and experts in public and
animal health from 12 European countries and the USA on
Cryptosporidium genotyping (71). The participants discussed
the need for, and potential directions of, a standardized typing
scheme specifically for surveillance and outbreak investigations.
There was general agreement that a robust multilocus genotyping
scheme should be developed through collaborative laboratory
studies, to standardize a method for meaningful interpretation of
genotype occurrence and distribution trends, and where possible
incorporate into national surveillance programs (71). To achieve
this multiple markers spread, sufficiently across the genome, are
required. The recent generation of genome data facilitates the
identification of markers that show potential to be combined
for MLG investigations specifically for surveillance and outbreak
investigations (15).
WHOLE GENOME SEQUENCING
While we aspire to using WGS routinely in public health
investigations of Cryptosporidium cases in the way it is applied to
some bacterial pathogens (72–74), the reality is that this is still a
way off. Direct sequencing would provide timely investigation of
public health incidents, but it poses a challenge for this parasite;
it is difficult to culture and bioinformatics pipelines have not
been validated for public health purposes as Cryptosporidium has
suffered from lack of prioritization in genomics programs.
The first technical problem is the amount of DNA that is
required. Although this varies depending on the technology
used, for example, the Nextera XT DNA kits that have been
used in several publications require 1 ng of DNA, and as each
oocyst contains 40 fg of DNA it means that 2.5 × 104 oocysts
are required without losses and in a practical volume (75). To
generate sufficient DNA, oocysts may be propagated through
animals, but Cryptosporidium populations have been shown
to change through natural host-based preferential selection of
individual subtypes or further recombination into new subtypes.
For example, the “isolate” that provided the first reference C.
hominis genome in 2004 (TU502) was subsequently serially
propagated in gnotobiotic pigs over many years resulting in a
different subtype in 2012, which was likely due to the original
population being overgrown by another contaminating isolate
(76). Additionally, the availability of host animals appropriate to
the Cryptosporidium species in question (Table 1), and the ethics,
time and cost resources that are associated with propagation are
prohibitive. As propagating oocysts is not a practical solution,
obtaining enough clinical sample is the next hurdle, as the volume
of stools often submitted is very small. Purity is also a challenge
because feces is the starting point, so Cryptosporidium DNA is
overshadowed by non-target DNA from the biome and host.
Lack of purity has been overcome by the combination of several
techniques including harvesting by flotation, further purifying
by immunomagnetic separation and using the natural chlorine
resistance of Cryptosporidium oocysts to surface-sterilize them
with bleach (75, 77).
The sufficiency of available Cryptosporidium DNA has
also been addressed through the use of whole genome
amplification (WGA) techniques, which now mean that very
small amounts of DNA, even from single oocysts, can be used
for genome sequencing (77, 78). Guo et al. used WGA to
enrichCryptosporidiumDNA from six discrete species/genotypes
extracted from 24 human and animal fecal samples (77).
The results were encouraging, showing that Cryptosporidium
DNA was significantly enriched, allowing for coverage of
> 94% of the genome (77). This ability to whole genome
sequence from very low numbers of oocysts is a development
that may help when investigating environmental samples and
other transmission pathways. Additionally, it may also alleviate
problems encountered when whole genome sequencing a mixed
population of oocysts. The concern that WGA could result in
higher numbers of errors introduced into the genome sequence
due to the fidelity of the enzymes used is also unfounded.
The presence of four sporozoite genomes in a single oocyst
helps, as any errors introduced in the first cycle are unlikely
to occur at exactly the same place in more than one genome,
so subsequent copies from the other genomes (containing the
correct sequence) should overshadow any errors. AlthoughWGS
technology has developed and some of the technical hurdles
have been overcome to enable direct sequencing (75, 77, 78),
we are still not at a point where it can be used to inform
in real-time for meaningful surveillance or during outbreak
investigations. Aside from technical and resource issues, the
lack of user-friendly, validated pipelines specifically designed
to generate data in a form that is useful to public health
practitioners during the management of incidents, make direct
whole genome sequencing currently impractical. Nevertheless,
genomic data are being used for biomarker discovery and to
understand genetic diversity in parasite populations in different
settings. These developments are described below, and arise from
the progression of Cryptosporidium whole genome sequencing
and assembly over the last two decades.
Progression of Whole Genome Sequencing
and Assembly
Attempts to sequence the genome of Cryptosporidium began
in the early 2000s. Initial attempts involved cloning sheared
fragments into plasmid vectors and Sanger sequencing. This
approach resulted in > 9x coverage of the genome and yielded
a fragmented assembly of 221 contigs of length > 5 kbp (79).
A more advanced sequencing project was undertaken to resolve
gaps, using large C. parvum fragments contained within lambda
DASH II libraries, and sequence missing DNA using a primer
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walk strategy (79). The completed genome of C. parvum (Iowa
II) along with a preliminary annotation was first published in
2004 by Abrahamsen et al. (80) who passaged oocysts through
an animal donor to produce enough parasitic material for the
extraction and purification of sufficient amounts of DNA. A
random shotgun sequencing approach was used, which yielded
a complete genome with coverage of 13x over 18 large contigs
(80) and was shortly followed by the publication of the first
draft genome of C. hominis (TU502) in late 2004. However, this
C. hominis genome proved to be much more fragmented than
that of C. parvum, resulting in a sequence consisting of 1,422
contigs (81).
In 2015, the C. parvum (Iowa II) reference genome was
reassembled and reannotated, and a new C. hominis reference
genome (UdeA01) published (82). The updated assembly
resolved all eight chromosomes from the 18 scaffolds in the
previous genome, representing the first chromosome level
assembly of C. parvum. The reannotation effort increased
the number of putative genes from 3807 to 3865 for
C. parvum Iowa II, and predicted the presence of 3819
genes in C. hominis UdeA01 (82). In 2016, Ifeonu et al.
reassembled and reannotated the C. hominis TU502 genome,
along with producing new draft genomes of human isolated
C. hominis (UKH1) and C. meleagridis (UKMEL1) along with
the avian species Cryptosporidium baileyi (TAMU-09Q1) (83).
The C. hominis TU502 genome proved to be a considerable
improvement on the previous 2004 version, being much more
complete, and reducing the number of contigs down to 119.
Annotation was facilitated by the RNAseq data generated from
the oocyst stage of both C. hominis and C. baileyi, predicting the
presence of 3745 protein coding genes in C. hominis TU502 and
3765 in C. hominis UKH1 (83).
As can be seen in Table 2, there is little difference between
the genomes of C. parvum and C. hominis. They exhibit 95–
97% DNA sequence identity; with 11 protein-coding sequences
identified only in C. hominis and 5 in C. parvum, and no large
indels or rearrangements apparent (84). The high conservation
in the C. hominis genomes generated from European samples
compared to the much more polymorphic C. parvum does not
appear to be expressed in general observations on structure
and base representation as illustrated in Table 2, suggesting
that phenotypic differences are potentially due to more subtle
sequence divergence (SNPs and Indels) and gene expression.
This further illustrates the importance of large-scale sequence
comparison of Cryptosporidium species to elucidate potentially
exploitable variation. Widmer et al. identified a number of highly
divergent genes by comparison of the genomes ofC. parvum gp60
subtype IIc and the Iowa II reference (85). Further investigation
reveals that genomic evolution was largely reductive, resulting
in Cryptosporidium depending mainly on host cells for basic
nutrients (86).
As more genomes are becoming available at an ever-
increasing rate, researchers are able to explore further the
biology and evolution of Cryptosporidium. Recently, Nader et al.
(87) used 21 whole genome sequences to show the existence
of two subspecies lineages of C. parvum (C. parvum parvum
and C. parvum anthroponosum) with different host-adapted
infectivity. Additionally, they identified some of the historic
genetic exchanges that have occurred between these lineages
and C. hominis during the evolution of these different species
and subspecies, even suggesting rough time-lines for when these
events occurred (87, 88).
In an important epidemiological development, Gilchrist et al.
(31) used the methods described by Hadfield et al. (75), to study
the genetic diversity of C. hominis in slum dwelling infants in
Dhaka, Bangladesh, over a 2-year period. As mentioned above,
they found that C. hominis was more abundant during the
monsoon periods and showed high levels of diversity at gp60
locus. Furthermore, WGS revealed extensive SNP diversity, and
very high levels of variation at seven distinct loci. They also
detected high levels of recombination within the C. hominis
populations, evidenced by linkage disequilibrium decay. The
genetic diversity of C. hominis encountered in the Bangladesh
study was found to be far greater than that seen in northern
Europe, where the predominant C. hominis IbA10G2 subtype
is highly conserved at the genome level (50, 71). This study
reveals the importance of high-throughput, wide scale genomic
sequencing and analysis in elucidating the complex population
structure of the parasite worldwide (31).
In another study, WGS was also used for a comparative
genomic analysis between two subtypes of C. hominis that
have been dominant in the US at various times, IbA10G2
and IaA28R4, and C. parvum (70). Their genome comparison
revealed evidence of genetic recombination in the two C. hominis
subtypes, and also some unique genetic differences between
C. hominis and C. parvum, and multigene families that may
contribute to the host variation between these two species (70).
Genome Availability
The advent of the new techniques to facilitate the DNA
extraction, enrichment, sequencing, and assembly of high
qualityCryptosporidium genomes from clinical samples, provides
TABLE 2 | The progression of C. hominis and C. parvum whole genome assembly from initial attempts in 2004 to the completed genomes in 2015 and 2016 (80–83).
Feature C. parvum Iowa
II (2004)
C. hominis
TU502 (2004)
C. hominis
UdeA01 (2015)
C. parvum Iowa
II (2015)
C. hominis
TU502 (2016)
Genome length 9.10 Mbp 9.16 Mbp 9.05 Mbp 9.10 Mbp 9.10 Mbp
Coding genes (% genome) 3807 (75.3%) 3994 (69%) 3819 (75.4%) 3865 (75.7%) 3745 (77.8%)
GC content 0.3 0.32 0.32 0.32 0.3
Introns 0.05 0.05-0.20 0.109 0.108 not reported
Fragments 18 1422 8 8 119
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FIGURE 3 | A comparison of the coverage over chromosome 1 of C. parvum Iowa II (top track) and the clinical isolate UKP3 (bottom track), showing the highly uneven
coverage typically exhibited from many clinical isolates. Reads were mapped using Bowtie v2.3.3.1 (93) and visualized using Integrative Genomics Viewer v2.4.16 (94).
an opportunity to greatly expand the number of genomes
available. An EU funded collaboration (Aquavalens project,
www.aquavalens.org) between several institutions generated 27
assemblies of C. parvum, C. hominis, Cryptosporidium viatorum,
C. ubiquitum, C. cuniculus, and C. meleagridis directly from
clinical isolates using the DNA extraction and purification
protocol described by Hadfield et al. (75) and Nader et al.
(87). Under another EU funded project, COMPARE (https://
www.compare-europe.eu/), 31 new C. parvum and 19 new
C. hominis genome assemblies were generated from clinical
isolates, using the DNA extraction and purification protocol
described by Hadfield et al. (75), and the DNA enrichment
protocol described by Guo et al. (77). A further 14 C. hominis
genomes, representing 9 different gp60 subtypes, have also been
published (89) and are available as a Bioproject (PRJNA307563)
on the National Center for Biotechnology Information (NCBI)
online databases. Currently, whole genome assemblies of isolates
from human and animal derived Cryptosporidium spanning 9
species, are available as Bioprojects on NCBI databases (see
Table 1), but this number is rapidly increasing as methods
and technology become more available. The Cryptosporidium
genomics resource CryptoDB (http://cryptodb.org/), provides
access to species including C. hominis, C. parvum, other zoonotic
species including C. meleagridis, and host-adapted species rarely
found in humans (Cryptosporidium muris, Cryptosporidium
andersoni, C. baileyi, and Cryptosporidium tyzzeri) and provides
analytical tools to mine and compare the genomes sequences
and their functionality (90, 91). A number of unassembled,
unprocessed raw read sequences are also publically available via
online repositories such as GenBank and the Welcome Trust
Sanger Institute FTP servers.
Sequencing Using Long-Read Technology
Recently, there have been attempts to generate Cryptosporidium
sequences using long-read technology, such as MinION by
Oxford Nanopore, and Pacific Biosciences. There exist a few
draft genomes from long reads generated by PacBio, but most
are yet unpublished. However, a C. parvum PacBio sequence is
available on the Welcome Trust Sanger Institute FTP servers
(ftp://ftp.sanger.ac.uk/project/pathogens/Cryptosporidium) that
was generated to map shorter Illumina reads to during the study
in Dhaka that explored the genetic diversity of C. hominis (31).
Currently, there have been no successful attempts at sequencing
the genome using the MinION platform published. This is likely
due to the large amount of DNA required to generate such reads
using this particular technology, which is a known difficulty
associated with Cryptosporidium genomic sequencing.
Pitfalls in Genome Assembly
Morris et al. have outlined difficulties associated with generating
reliable and accurate genome assemblies from clinical isolates
of Cryptosporidium (92). They demonstrated that the issues
surrounding extracting sufficient DNA from clinical isolates
resulted in highly uneven depth of coverage across the genome
(for an example, see Figure 3) which can be seen in sequences
generated from clinical isolates by a number of research teams.
This, in tandem with the large number of low complexity regions
within the Cryptosporidium genome, results in widespread
genomemisassembly when using the Spades assembler (95). Peng
et al. further proposed an approach to generating reliable draft
assemblies from clinical samples, and demonstrated how accurate
resolution of low complexity regions are essential for biomarker
discovery using the Iterative De-Bruijn Assembler (IDBA) (96).
Assembly of C. parvum and C. hominis is facilitated by high
quality reference sequences (C. parvum IowaII and C. hominis
UdeA01) which allow for reference-guided assembly. This,
however, is not the case for other species of Cryptosporidium. It
is therefore important to consider whether a reference guided
assembly should be attempted, and what reference genome to
use. The application of an inappropriate reference sequence may
result genome assembly errors.
APPLICATIONS, FUTURE ISSUES, AND
RESEARCH DIRECTIONS
With the recent expansion in the number of available raw read
archives and genome assemblies generated from clinical samples,
further in silico investigation can be carried out in an attempt to
resolve a number of biological questions, such as:
• Can biomarkers differentiate genetic lineages of
Cryptosporidium spp. virulence or pathogenicity, and
therefore act as targets for diagnostic interrogation or
novel therapeutics?
Frontiers in Public Health | www.frontiersin.org 10 December 2019 | Volume 7 | Article 360
Morris et al. Sequencing Cryptosporidium for Public Health
• How much variability exists within intergenic regions in
species of Cryptosporidium?
• To what extent do multiple sub-populations of
Cryptosporidium spp. exist within an infected host
and in single clinical samples and impact of these
during onward transmission and even the evolution of
the parasite?
Biomarker Discovery and Analysis
The state ofCryptosporidium genotyping is far from resolved, and
there is still a large amount of work to be done regarding the
discovery, assessment, and selection of suitable biomarkers and
genotyping conventions. Subsequent to the increasing availability
of genomes is a bottle-neck in the analysis of these data, and there
is a need to develop time-efficient, computationally inexpensive
and high-throughput (automated) methods of genome analysis.
“In house” pipelines have been used for biomarker detection
and analysis. A typical example was reported by Perez-Cordon
et al. (15), who used Tandem Repeats Finder (TRF) (97) to
detect Variable Number Tandem Repeat (VNTR) regions within
the genome of Cryptosporidium parvum Iowa II isolate and
aligned them to homologues within a dataset of genomes
generated by Hadfield et al. (75). This pipeline consisted of three
primary steps:
1. Tandem Repeat (TR) identification in a reference genome.
2. Discovery of the TR’s around the genome of a dataset of
assembled genomes.
3. Assessment of these TR’s for variation and subsequent viability
as Biomarkers.
Using this pipeline, bioinformatic analysis of the Hadfield dataset
alone has yielded a large number of novel VNTR regions (15),
some of which compare favorably to the commonly used gp60
marker in their ability to resolve discrete subtypes of C. parvum.
Automating pipelines, can utilize the increasing amounts of
whole genome sequence data available for Cryptosporidium
allowing for the discovery of novel VNTRs in a high-
throughput manner.
In addition to novel VNTR markers, genome analysis of
other Cryptosporidium species and genotypes can allow for the
redescription of known markers in these for the development
of new subtyping tools. One example, is with the zoonotic
species Cryptosporidium ubiquitum, where the homolog of gp60
was diverse from those of C. hominis and C. parvum so could
not be used to differentiate isolates (46). Li et al. used whole
genome sequence data to identify and develop a gp60 subtyping
tool that allowed the differentiation and showed apparent host-
adaptation (46). Another example, described the development
from whole genome sequencing data of a two marker subtyping
tool (gp60 and a mucin protein gene) for the zoonotic chipmunk
genotype I (98).
When developing genotyping assays, it is important that
biomarkers are selected so as not to influence the outcome of
the analysis. For example, markers must be distant enough from
each other on the same chromosome or spread over the eight
chromosomes to ensure genetic linkage does not occur, and
markers must give high enough discrimination when combined
to be appropriate for the application in question, such as
demonstrating epidemiological relationships (27, 84).
Multiplicity of Infection in Cryptosporidium
It is both biologically plausible (due to unrestricted sexual
recombination between sub-populations), and there is strong
evidence (described below) that infections can arise from,
and give rise to, multiple sub-populations of Cryptosporidium
spp. which will be present in individual hosts (termed here
multiplicity of infection—MOI) and thus clinical samples. This
is driven by meiotic division in the zygote resulting in potential
re-assortment of chromosomes (Figure 2b). As a result, the
genomes of the haploid sporozoites within an oocyst may
differ from each other and the parent sporozoites. Grinberg
and Widmer demonstrated the common occurrence of MOI
and provided evidence that the degree of MOI may depend
on prevailing transmission patterns within geographical regions
(25). The current approaches of Sanger sequencing results
in the resolution of a single allele at each locus for the
population, which, if MOI is present, would in effect simply
represent the most populous sequence variant at each locus
within the assembly. Grinberg and Widmer illustrated this
from three hypothetical infections (25), but the potential extent
for MOI is theoretically even greater (Figure 2b). This may
confound epidemiological analysis, which generally relies on
the assumption that large-scale genetic recombination does not
occur within a host, and that a single host exhibits a single,
clonal population. Furthermore, it has been suggested that MOI
is a driving force behind the evolution of virulence, and has a
complex relationship with both the virulence experienced by the
host, and transmission (99, 100). It is therefore essential thatMOI
is well-understood and accounted for in order to develop novel
prevention strategies in the fight against cryptosporidiosis and
other parasitic diseases. The investigation into the impact of MOI
relies on the accurate and reliable detection and discrimination of
discrete populations of parasites, not readily achieved by current
genotyping approaches. There are a few major alternatives to
achieve this:
• Cloning and sequencing key loci to detect variation.
• Isolating and sequencing single oocysts from clinical samples.
• Comparing length polymorphism at multiple loci.
• Investigating sequence variation among reads within
short read archives generated by Next Generation
Sequencing (NGS).
These approaches investigate MOI from very different angles:
variable locus cloning and single cell sequences from an
experimental angle, and length polymorphism and sequence
variation within reads from an in silico angle. This lends them
unique challenges to overcome. By cloning PCR amplicons of
selected loci (gp60 and hsp70) and utilizing Next Generation
Sequencing (NGS), Grinberg et al. reported the presence of
numerous sub-populations within single isolates of C. parvum.
They demonstrated the presence of two hsp70 and 10 gp60 alleles
within their two isolate dataset. Furthermore, they reported that
in both isolates there was a dominant allele, which represented
the majority of the amplicons sequenced (101). Single oocysts
were isolated and sequenced by Troell et al. (78) with a
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view to elucidate these putative intra-isolate sub-populations.
Sequencing 10 oocysts individually resulted in assemblies of
49.4–91.8% of the size of the C. parvum Iowa II reference
genome. By pooling the reads from all 10 oocysts, they generated
a 94.4% complete genome. Variation at multiple loci was
detected between the assembled genomes, verifying the presence
of discrete populations within the “isolate” (78). Analysis of
fragment length polymorphism can highlight MOI, however, due
to PCR-based amplification of the fragments, minority variants
are largely undetectable (25). To compare the results obtained
from Sanger sequencing and NGS, Zahedi et al. investigated
gp60 amplicons from 11 C. hominis, 22 C. parvum, and 8 C.
cuniculus animal samples from Australia and China (102). They
demonstrated that NGS ismore effective at resolving the presence
of multiple populations of Cryptosporidium within a sample,
and the extent of MOI. There was concordance between the
subtypes identified by both platforms, but additional subtypes
were identified using NGS on C. parvum and C. cuniculus gp60
amplicons, but not C. hominis.
The major issue with the experimental approaches detailed
above is that they are expensive, extremely labor intensive and
time consuming, leading to poor scalability. This leads to a
major problem in generating sufficient data with which to begin
to unravel the role of these parasite sub-populations, and to
understand their overall impact on global public health. It is
expected that they will have roles in affecting transmission
by reducing host-fitness (virulence), and in generating novel
subtypes via sexual recombination. There is therefore a great need
to develop strategies which allow us to carry out investigations in
a high-throughput manner, utilizing the wealth of raw genomic
data is available for Cryptosporidium and other related parasites.
Using biomarkers discovered from the analysis of the increasing
number of high quality genomes, the opportunity arises to start
to investigate MOI using in silico techniques, by mining raw
read sets sequenced from clinical samples for information, which
may have been previously unattainable. This approach involves
three stages:
1. Identification of target regions for read interrogation. It is
essential to select target regions, which are likely to show
variation in-host, and it is therefore wise to select loci which
show large amounts of variation between hosts.
2. Identification of reads within a single-host read set which have
captured the target region.
3. Assessment of variation of the target sequence amongst reads
which were identified in step 2.
A high level of variation within a single-host read set indicates
the presence of multiple populations. Preliminary analysis of
the Hadfield et al. dataset (75) indicated extensive variation
at multiple tandem repeat loci around the Cryptosporidium
genome, indicating highly complex in-host population structure.
Results for variance mining at the gp60 locus can be seen in
Figure 4, which shows high levels of fragment length variation.
However, there is invariably a single allele which appears to be
FIGURE 4 | The distribution of fragment lengths at the gp60 locus mined from raw read sets generated from human clinical samples of UK isolated C. parvum by
Hadfield et al. (75). Fragment lengths are given in the legend. n refers to the number of reads which fully captured the gp60 region, and are therefore presented in
the data.
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most frequently exhibited within reads, and therefore considered
dominant. This is in agreement with the findings reported by
others, which show similar population structure (78, 101). There
is, however, a disparity in the extent of MOI in Cryptosporidium
between laboratory evidence by fragment sizing of key loci, and
by mining NGS data. This is potentially due to the limited
sensitivity of such approaches to identify multiple alleles of
similar fragment size. Furthermore, PCR may preferentially
amplify more abundant alleles, resulting in the less abundant
alleles being obscured, as shown by Grinberg et al. who initially
only identified the predominant alleles in their samples by PCR
and Sanger sequencing (101). It may also be the case that such
studies were not designed to detect multiple alleles within a
single sample, and therefore underestimate the incidence of
MOI. Consequently, care should be taken when interpreting
entirely in silico results in the absence of experimental data. Due
to MOI being a new area of investigation in Cryptosporidium
research, the reliability of in silico approaches to elucidate in-
host population diversity is still unclear, particularly in the
light of studies indicating extensive contamination of samples
(77). Preliminary results, however, appear to make predictions
which are in accordance with experimental and epidemiological
evidence, giving confidence in such data.
Natural transmission studies from analyzing secondary
infections and those in farm settings has shown that dominant
subtypes can be stable for many years or they can vary from
year to year. For example, the outbreaks among visiting children
on a holiday farm in Norway showed the same gp60 subtype,
IIaA19G1R1, was still circulating over several years and an
investigation into secondary transmission within households
after the children returned home also found the same subtype
(103). While there was no evidence at the gp60 gene of mixed
populations in this example, in farm settings it is common
for multiple subtypes to be present (104, 105). During a
study of household transmission in a rural and urban setting
in Bangladesh, a wide variety of gp60 subtypes were found,
particularly in the urban setting, but often there were concurrent
infections with the same subtype within households and
therefore it was mostly impossible to know the directionality of
transmission (106). Where there were different subtypes within
households it is unclear whether these stemmed from external
sources rather than secondary transmission within the household
(106). However, despite these studies there is a lack of data
from mixed natural infections and the changes or dominance of
subtypes that may occur during onward transmission, something
that warrants further investigation using multilocus tools or
whole genome data. Cama et al. used MLST to characterize
differences in Iowa reference C. parvum isolates that had been
maintained in different laboratories and described differences
that were likely the results of passages through calves infected
with exogenous C. parvum (107). This genetic drift in reference
isolates was also seen with the TU502 reference C. hominis isolate
between 2005 and 2012 following multiple animal passages (76).
Therefore, the implications of MOI for surveillance and outbreak
investigations are uncertain. As drift may happen in the longer
term but not necessarily in the short term, detecting an outbreak
“type” is reasonable, but equally it could be that two cases with
apparently different subtypes are still actually linked if there is
bias in the detection of dominant alleles.
CONCLUSIONS
WGS holds tantalizing promise for better understanding the
transmission of cryptosporidosis, but there are still good reasons
as to why it is not used routinely for diagnostics in a clinical
setting. These include issues with extracting high quality pure
DNA from clinical samples and issues with uneven depth of
read coverage that leads to gaps in the assembled genome
sequence. This later issue has important implications for cost:
reducing costs by sequencing at a low depth of coverage is
problematic, because it will increase the size and frequency of
gaps in the assembled genome sequences. Nonetheless, while
WGS is not yet on the horizon as method for routine clinical
genotyping, it is indirectly having an important influence on
clinical diagnostics. For instance, WGS is being used to guide
and inform the development of MLST schemes, such as those
based on VNTRs and fragment sizing. It is providing key insights
into the evolutionary development ofCryptosporidium, including
the discovery of new subspecies. Perhaps most important in
terms of understanding the transmission of the disease, WGS
is providing key insights into MOI. While evidence for MOI
is occasionally found using fragment sizing, preliminary WGS
analysis shows that is it is much more prevalent than the
evidence from fragment sizing might suggest. WGS shows that
although clinical samples do indeed contain multiple alleles,
a single highly abundant allele usually dominates the data
sets. It is highly likely that only the dominant allele that is
detected via fragment sizing, with the other alleles remaining
undetected. Resolution of these multiple populations is a
stepping-stone to understanding the driving factors behind the
evolution of virulence, and how new subtypes and genotypes arise
in Cryptosporidium.
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